Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;8(1):24-32.
doi: 10.1007/s13193-016-0591-4. Epub 2016 Dec 15.

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies

Vasanthakumar Sekar  1 , Debapriya Ghosh Mehrotra  2 , Biswanath Majumder  2
Affiliations
Review

Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies

Vasanthakumar Sekar et al. Indian J Surg Oncol. 2017 Mar.

Abstract

Urological malignancies, represented mainly by prostate, bladder, and renal cancers, are some of the leading causes of cancer-related mortalities worldwide. Despite various efforts over decades to develop early detection tests and effective therapeutic paradigms, the response rate to the existing treatments remains low for both primary and late stage/recurrent phases of these cancers. The evolving landscape of molecular diagnostics, aiming to make the diagnosis and treatment more patient-driven, underpins precision oncology and particularly intends to rationally profile individual tumors and highlight the mechanistic insight and complexity of tumor microenvironment in order to develop biomarkers of toxicity risks and response prediction in a clinically oriented dynamical setting. The present review is an effort to capture some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies.

Keywords: Ex vivo models; Precision therapy; Prediction biomarkers; Urological cancer.

PubMed Disclaimer

References

    1. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, et al. Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol. 2008;15:4056–4064. - PMC - PubMed
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics. 2003;21:1315–1330. doi: 10.1007/BF03262330. - DOI - PubMed
    1. Moyer VA. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157:120–134. doi: 10.7326/0003-4819-157-2-201207170-00459. - DOI - PubMed
    1. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013;5:318–329. doi: 10.1177/1756287213495915. - DOI - PMC - PubMed
    1. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377. doi: 10.1056/NEJM200105033441806. - DOI - PubMed